Cargando…

Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients

Standard lipid-lowering therapies in solid organ transplantations pose challenges due to interactions with immunosuppressants. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) represent a new class of lipid-lowering therapies with potential promise in this population. We describe PC...

Descripción completa

Detalles Bibliográficos
Autores principales: Warden, Bruce A., Kaufman, Tina, Minnier, Jessica, Duell, P. Barton, Fazio, Sergio, Shapiro, Michael D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311616/
https://www.ncbi.nlm.nih.gov/pubmed/34317250
http://dx.doi.org/10.1016/j.jaccas.2019.09.026
_version_ 1783728994672181248
author Warden, Bruce A.
Kaufman, Tina
Minnier, Jessica
Duell, P. Barton
Fazio, Sergio
Shapiro, Michael D.
author_facet Warden, Bruce A.
Kaufman, Tina
Minnier, Jessica
Duell, P. Barton
Fazio, Sergio
Shapiro, Michael D.
author_sort Warden, Bruce A.
collection PubMed
description Standard lipid-lowering therapies in solid organ transplantations pose challenges due to interactions with immunosuppressants. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) represent a new class of lipid-lowering therapies with potential promise in this population. We describe PCSK9i as an efficacious and safe option for management of hypercholesterolemia in solid organ transplantations. (Level of Difficulty: Advanced.)
format Online
Article
Text
id pubmed-8311616
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-83116162021-07-26 Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients Warden, Bruce A. Kaufman, Tina Minnier, Jessica Duell, P. Barton Fazio, Sergio Shapiro, Michael D. JACC Case Rep Mini-Focus Issue on Heart Failure Standard lipid-lowering therapies in solid organ transplantations pose challenges due to interactions with immunosuppressants. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) represent a new class of lipid-lowering therapies with potential promise in this population. We describe PCSK9i as an efficacious and safe option for management of hypercholesterolemia in solid organ transplantations. (Level of Difficulty: Advanced.) Elsevier 2020-02-12 /pmc/articles/PMC8311616/ /pubmed/34317250 http://dx.doi.org/10.1016/j.jaccas.2019.09.026 Text en © 2020 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Mini-Focus Issue on Heart Failure
Warden, Bruce A.
Kaufman, Tina
Minnier, Jessica
Duell, P. Barton
Fazio, Sergio
Shapiro, Michael D.
Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients
title Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients
title_full Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients
title_fullStr Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients
title_full_unstemmed Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients
title_short Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients
title_sort use of pcsk9 inhibitors in solid organ transplantation recipients
topic Mini-Focus Issue on Heart Failure
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311616/
https://www.ncbi.nlm.nih.gov/pubmed/34317250
http://dx.doi.org/10.1016/j.jaccas.2019.09.026
work_keys_str_mv AT wardenbrucea useofpcsk9inhibitorsinsolidorgantransplantationrecipients
AT kaufmantina useofpcsk9inhibitorsinsolidorgantransplantationrecipients
AT minnierjessica useofpcsk9inhibitorsinsolidorgantransplantationrecipients
AT duellpbarton useofpcsk9inhibitorsinsolidorgantransplantationrecipients
AT faziosergio useofpcsk9inhibitorsinsolidorgantransplantationrecipients
AT shapiromichaeld useofpcsk9inhibitorsinsolidorgantransplantationrecipients